Abstract #0680
Using Radiogenomics to Characterize MRI-Guided Prostate Cancer Biopsy Heterogeneity
Radka Stoyanova 1 , Alan Pollack 1 , Nicholas Erho 2 , Charles Lynne 3 , Lucia Lam 2 , Christine Buerki 2 , Sakhi Abraham 1 , Merce Jorda 4 , Olexandr Kryvenko 4 , Matthew Abramowitz 1 , Elai Davicioni 2 , and Adrian Ishkanian 1
1
Radiation Oncology, University of Miami,
Miami, Florida, United States,
2
GenomeDx
Biosciences, Vancouver, British Columbia, Canada,
3
Urology,
University of Miami, Miami, Florida, United States,
4
Pathology,
University of Miami, Miami, Florida, United States
Current clinicopathological factors explain just a
fraction of the observed heterogeneity in prostate
cancer patient outcome. In this study we address the
question whether quantitative imaging data from
multiparametric (MP)-MRI are associated with gene
expression characteristics (radiogenomics) and how these
in turn relate to Gleason score (GS) and intra-patient
versus inter-patient genomic heterogeneity. Quantitative
MP-MRI-targeted diagnostic biopsies can potentially
improve risk classification by directing pathological
and genomic analysis to highest risk index lesions. This
is the first demonstration of a link between
quantitative imaging features (radiomics) with genomic
features in MRI-directed prostate biopsies.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
